Spots Global Cancer Trial Database for Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)

Official Title: A Phase 2 Study of Nivolumab Plus Ipilimumab in Previously Treated Classical Kaposi Sarcoma (CKS)

Study ID: NCT03219671

Conditions

Classic Kaposi Sarcoma

Interventions

Nivolumab

Ipilimumab

Study Description

Brief Summary: A Phase 2 study of nivolumab plus ipilimumab in previously treated classical Kaposi Sarcoma (CKS)

Detailed Description: A prospective, single arm, interventional study. All patients will receive IV nivolumab 3mg/kg every two weeks and ipilimumab 1mg/kg every 6 weeks. Patients will be treated until disease progression or intolerable toxicity for a maximal period of two years, with an option to re-initiate therapy upon progression in patients with prior documented response to investigational therapy (unless treatment was held for progression of disease).